vs
ACADIA PHARMACEUTICALS INC（ACAD）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
ACADIA PHARMACEUTICALS INC的季度营收约是Prestige Consumer Healthcare Inc.的1.0倍（$284.0M vs $283.4M），ACADIA PHARMACEUTICALS INC净利率更高（96.3% vs 16.5%，领先79.9%），ACADIA PHARMACEUTICALS INC同比增速更快（9.4% vs -2.4%），过去两年ACADIA PHARMACEUTICALS INC的营收复合增速更高（17.5% vs 1.2%）
阿卡迪亚制药是一家总部位于美国加利福尼亚州圣地亚哥德尔马地区的生物制药企业，专注于中枢神经系统相关疾病治疗药物的研发、生产与商业化，致力于为全球患者提供创新的临床治疗方案。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
ACAD vs PBH — 直观对比
营收规模更大
ACAD
是对方的1.0倍
$283.4M
营收增速更快
ACAD
高出11.8%
-2.4%
净利率更高
ACAD
高出79.9%
16.5%
两年增速更快
ACAD
近两年复合增速
1.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $284.0M | $283.4M |
| 净利润 | $273.6M | $46.7M |
| 毛利率 | 90.8% | 55.5% |
| 营业利润率 | 6.1% | 29.1% |
| 净利率 | 96.3% | 16.5% |
| 营收同比 | 9.4% | -2.4% |
| 净利润同比 | 90.3% | -23.5% |
| 每股收益（稀释后） | $1.61 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACADPBH
| Q4 25 | $284.0M | $283.4M | ||
| Q3 25 | $278.6M | $274.1M | ||
| Q2 25 | $264.6M | $249.5M | ||
| Q1 25 | $244.3M | $296.5M | ||
| Q4 24 | $259.6M | $290.3M | ||
| Q3 24 | $250.4M | $283.8M | ||
| Q2 24 | $242.0M | $267.1M | ||
| Q1 24 | $205.8M | $277.0M |
净利润ACADPBH
| Q4 25 | $273.6M | $46.7M | ||
| Q3 25 | $71.8M | $42.2M | ||
| Q2 25 | $26.7M | $47.5M | ||
| Q1 25 | $19.0M | $50.1M | ||
| Q4 24 | $143.7M | $61.0M | ||
| Q3 24 | $32.8M | $54.4M | ||
| Q2 24 | $33.4M | $49.1M | ||
| Q1 24 | $16.6M | $49.5M |
毛利率ACADPBH
| Q4 25 | 90.8% | 55.5% | ||
| Q3 25 | 92.2% | 55.3% | ||
| Q2 25 | 92.2% | 56.2% | ||
| Q1 25 | 91.7% | 57.3% | ||
| Q4 24 | 91.6% | 55.5% | ||
| Q3 24 | 92.5% | 55.5% | ||
| Q2 24 | 92.5% | 54.7% | ||
| Q1 24 | 88.8% | 54.8% |
营业利润率ACADPBH
| Q4 25 | 6.1% | 29.1% | ||
| Q3 25 | 12.8% | 29.1% | ||
| Q2 25 | 12.2% | 28.8% | ||
| Q1 25 | 7.9% | 29.8% | ||
| Q4 24 | 59.1% | 31.7% | ||
| Q3 24 | 12.6% | 29.7% | ||
| Q2 24 | 12.6% | 27.0% | ||
| Q1 24 | 7.4% | 29.7% |
净利率ACADPBH
| Q4 25 | 96.3% | 16.5% | ||
| Q3 25 | 25.8% | 15.4% | ||
| Q2 25 | 10.1% | 19.0% | ||
| Q1 25 | 7.8% | 16.9% | ||
| Q4 24 | 55.4% | 21.0% | ||
| Q3 24 | 13.1% | 19.2% | ||
| Q2 24 | 13.8% | 18.4% | ||
| Q1 24 | 8.0% | 17.9% |
每股收益（稀释后）ACADPBH
| Q4 25 | $1.61 | $0.97 | ||
| Q3 25 | $0.42 | $0.86 | ||
| Q2 25 | $0.16 | $0.95 | ||
| Q1 25 | $0.11 | $1.00 | ||
| Q4 24 | $0.86 | $1.22 | ||
| Q3 24 | $0.20 | $1.09 | ||
| Q2 24 | $0.20 | $0.98 | ||
| Q1 24 | $0.10 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.7M | $62.4M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $1.2B | $1.8B |
| 总资产 | $1.6B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.56× |
8季度趋势，按日历期对齐
现金及短期投资ACADPBH
| Q4 25 | $177.7M | $62.4M | ||
| Q3 25 | $258.0M | $119.1M | ||
| Q2 25 | $253.6M | $139.5M | ||
| Q1 25 | $217.7M | $97.9M | ||
| Q4 24 | $319.6M | $50.9M | ||
| Q3 24 | $155.1M | $51.5M | ||
| Q2 24 | $177.1M | $34.3M | ||
| Q1 24 | $204.7M | $46.5M |
总债务ACADPBH
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
股东权益ACADPBH
| Q4 25 | $1.2B | $1.8B | ||
| Q3 25 | $917.3M | $1.8B | ||
| Q2 25 | $822.4M | $1.9B | ||
| Q1 25 | $765.2M | $1.8B | ||
| Q4 24 | $732.8M | $1.8B | ||
| Q3 24 | $577.2M | $1.7B | ||
| Q2 24 | $516.7M | $1.7B | ||
| Q1 24 | $464.0M | $1.7B |
总资产ACADPBH
| Q4 25 | $1.6B | $3.5B | ||
| Q3 25 | $1.3B | $3.4B | ||
| Q2 25 | $1.2B | $3.4B | ||
| Q1 25 | $1.1B | $3.4B | ||
| Q4 24 | $1.2B | $3.3B | ||
| Q3 24 | $976.9M | $3.3B | ||
| Q2 24 | $914.1M | $3.3B | ||
| Q1 24 | $855.1M | $3.3B |
负债/权益比ACADPBH
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-48.7M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | — | $75.3M |
| 自由现金流率自由现金流/营收 | — | 26.6% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | -0.18× | 1.68× |
| 过去12个月自由现金流最近4个季度 | — | $267.2M |
8季度趋势，按日历期对齐
经营现金流ACADPBH
| Q4 25 | $-48.7M | $78.3M | ||
| Q3 25 | $74.3M | $57.5M | ||
| Q2 25 | $64.0M | $79.0M | ||
| Q1 25 | $20.3M | $61.8M | ||
| Q4 24 | $40.4M | $65.1M | ||
| Q3 24 | $63.2M | $69.8M | ||
| Q2 24 | $25.0M | $54.8M | ||
| Q1 24 | $29.1M | $66.9M |
自由现金流ACADPBH
| Q4 25 | — | $75.3M | ||
| Q3 25 | $73.9M | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | $63.2M | $67.8M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $63.8M |
自由现金流率ACADPBH
| Q4 25 | — | 26.6% | ||
| Q3 25 | 26.5% | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | 25.2% | 23.9% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 23.0% |
资本支出强度ACADPBH
| Q4 25 | — | 1.1% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.1% |
现金转化率ACADPBH
| Q4 25 | -0.18× | 1.68× | ||
| Q3 25 | 1.03× | 1.36× | ||
| Q2 25 | 2.40× | 1.66× | ||
| Q1 25 | 1.07× | 1.23× | ||
| Q4 24 | 0.28× | 1.07× | ||
| Q3 24 | 1.93× | 1.28× | ||
| Q2 24 | 0.75× | 1.12× | ||
| Q1 24 | 1.76× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
